このサービスはあなたの地域では利用できません。

6 4 G LTD

イギリス

設立年

2015 (11 年)

設立

最終オンライン: 最近の活動なし

ウェブサイトにアクセス

TrustScore は利用できませんトレンドを表示するのに十分なスコアがありません。

この会社で最初に評価・レビューしましょう。

総合スコア

ライセンス

--/40

レビュー

--/60

レビュー 0 件

TrustFinance提供

TrustScore は利用できませんトレンドを表示するのに十分なスコアがありません。

この会社で最初に評価・レビューしましょう。

FTD LIMITED

(505 レビュー)

British Virgin Islands

2017

(9 年)

セキュリティ情報 :

BVI FSC

セキュリティ情報

警告

この会社は現在未証明.

潜在的なリスクにご注意ください！

ライセンス

A級ライセンス

世界的に有名な規制当局によって発行されたこれらのライセンスは、厳格なコンプライアンス、資金の分別管理、保険、定期的な監査を通じて、トレーダーを最大限に保護します。紛争解決とAML/CTF基準の遵守は、セキュリティをさらに強化します。

B級ライセンス

尊敬される地域規制当局によって付与されたこれらのライセンスは、資金の分別管理、財務報告、補償制度などの強固な安全対策を提供します。ティア1ほど厳格ではありませんが、信頼できる地域保護を提供します。

C級ライセンス

新興市場の規制当局によって発行されたこれらのライセンスは、最低資本要件やAMLポリシーなどの基本的な保護を提供します。監督はそれほど厳格ではないため、トレーダーは注意して安全対策を確認する必要があります。

D級ライセンス

監督が最小限の司法管轄区からのこれらのライセンスは、資金の分別管理や保険などの重要な保護を欠いていることがよくあります。運用上の柔軟性には魅力的ですが、トレーダーにとってのリスクが高くなります。

会社情報

知り合う 6 4 G LTD

会社情報

知り合う 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

産業

外国為替小売ブローカー主要
金融他のサービス

ソフトウェア

データがありません

このセクションは空のようです。すぐに更新情報をお待ちください！

お問い合わせ

ソーシャル

会社は情報を更新していません。

レビュー

6 4 G LTD レビュー

レビュー

合計 0

ソート

フィルター

会社情報

知り合う 6 4 G LTD

会社情報

知り合う 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

産業

外国為替小売ブローカー主要
金融他のサービス

ソフトウェア

データがありません

このセクションは空のようです。すぐに更新情報をお待ちください！

お問い合わせ

ソーシャル

会社は情報を更新していません。

ニュース

TrustFinance 情報機関

調査日: 5月 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

TrustFinance AI分析による提供

ニュース

TrustFinance 情報機関

調査日: 5月 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

TrustFinance AI分析による提供

6 4 G LTD

FTD LIMITED

会社情報

会社情報

レビュー

6 4 G LTD レビュー

レビュー

合計 0

6 4 G LTD

FTD LIMITED

会社情報

会社情報

6 4 G LTD を見ているユーザーは他にも…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

ニュース

TrustFinance 情報機関

レビュー

6 4 G LTD レビュー

レビュー

合計 0

6 4 G LTD を見ているユーザーは他にも…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

ニュース

TrustFinance 情報機関